Evidence map›Paper›PMID 25085355›Full record

ArticleHaematologica2014

Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia.

Ann-Charlotte Bergh, Chamilly Evaldsson, Lone Bredo Pedersen, Christian Geisler, Kostas Stamatopoulos, Richard Rosenquist, Anders Rosén

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  5. Article
  6. The analysis of clonal expansions in normal and autoimmune B cell repertoires.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Ann-Charlotte BerghDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Chamilly EvaldssonDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Lone Bredo PedersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Christian GeislerDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Kostas StamatopoulosDepartment of Hematology and HCT Unit G. Papanicolaou Hospital, Thessaloniki, Greece Institute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Richard RosenquistDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Anders RosénDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden Anders.Rosen@liu.se.
Linköping University · SERigshospitalet · DKG. Papanikolaou General Hospital · GRScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia B cells express auto/xeno antigen-reactive antibodies that bind to self-epitopes and resemble natural IgM antibodies in their repertoire. One of the antigenic structures recognized is oxidation-induced malonedialdehyde that is present on low-density lipoprotein, apoptotic blebs, and on certain microbes. The poor-prognostic stereotyped subset #1 (Clan I IGHV genes-IGKV1(D)-39) express IgM B-cell receptors that bind oxidized low-density lipoprotein. In this study, we have used for the first time this authentic cognate antigen for analysis of downstream B-cell receptor-signal transduction events, since it is more faithful to B-cell physiology than anti-IgM. Multivalent oxidized low-density lipoprotein showed specific binding to subset #1 IgM/IgD B-cell receptors, whereas native low-density lipoprotein did not. The antigen binding induced prompt receptor clustering followed by internalization. However, the receptor-signal transduction was silenced, revealing no Ca(2+) mobilization or cell-cycle entry, while phosphorylated extracellular-regulated kinase 1/2 basal levels were high and could not be elevated further by oxidized low-density lipoprotein. Interestingly, B-cell receptor responsiveness was recovered after 48-h culture in the absence of antigen in half of the cases. Toll-like receptor 9-ligand was found to breach the B-cell receptor-signaling incompetence in 5 of 12 cases pointing to intra-subset heterogeneity. Altogether, this study supports B-cell receptor unresponsiveness to cognate self-antigen on its own in poor-prognostic subset #1 chronic lymphocytic leukemia, indicating that these cells proliferate by other mechanisms that may override B-cell receptor silencing brought about in a context of self-tolerance/anergy. These novel findings have implications for the understanding of chronic lymphocytic leukemia pathobiology and therapy.

Indexed as

Gene SilencingAutoantigensB7-2 AntigenCalciumCell CycleHumansImmunoglobulin Heavy ChainsImmunoglobulin J-ChainsImmunoglobulin MImmunoglobulin Variable RegionInterleukin-10Interleukin-2 Receptor alpha SubunitInterleukin-6Leukemia, Lymphocytic, Chronic, B-CellLigandsLipoproteins, LDLAutoantigensB7-2 AntigenCalciumImmunoglobulin Heavy ChainsImmunoglobulin J-ChainsImmunoglobulin MImmunoglobulin Variable RegionInterleukin-10Interleukin-2 Receptor alpha SubunitInterleukin-6LigandsLipoproteins, LDLoxidized low density lipoproteinReceptors, Antigen, B-CellToll-Like Receptor 9

Identifiers

PMID25085355
PMCPMC4222481
OpenAlexW2092003710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.